Published April 28, 2026 | Version v1
Preprint Open

Checkpoint Inhibitor Combination (Nivolumab/Ipilimumab) for Treatment-Refractory Extramammary Paget Disease

Authors/Creators

  • 1. MedicOath

Description

ClinicalTrials.gov NCT02834013 tests nivolumab and ipilimumab in rare tumors including EMPD. Open Payments reports successful 'tislelizumab plus chemotherapy in metastatic extramammary Paget disease' (2024). Dual checkpoint blockade enhances T-cell mediated tumor killing through PD-1 and CTLA-4 inhibition.

Notes

IPFS: QmWWYst9o77rr1ixQ9DuuQ4H49kictdY4qrE4BZd1DgSsK. TX: 0x102b63c09364d06540f406f8e05b051ed8c56adb575ef645444264a359fc93a5. CC0.

Files

hypothesis.json

Files (404 Bytes)

Name Size Download all
md5:ecdfdbf40dd0a21a55825cef6208dd23
404 Bytes Preview Download